Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis

Aortic Valve Stenosis Clinical Trial

— Venus-A  

Official title:

Clinical Evaluation of the Safety and Performance of Percutaneous Implantation of the Venus MedTech Aortic Valve Prosthesis for Patients Who Cannot Undergo Surgical Valve Replacement

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01683474
• Other study ID #: Venus-A Study
• Status: Recruiting
• Phase: N/A
• First received: September 7, 2012
• Last updated: January 3, 2015
• Start date: September 2012
• Est. completion date: April 2016

Study information

• Verified date: January 2015
• Source: Venus MedTech (HangZhou) Inc.
• Contact: Runlin Gao, MD
• Phone: 88398866
• Email: gaorunlin4study[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

1. objectives

• Evaluate the performance of Venus MedTech aortic valve prosthesis intervention by femoral artery

• Evaluate safety and clinical benefit of percutaneous implantation of the Venue MedTech aortic valve prosthesis.

• Continuous observe 12 months of safety and efficacy.

2. Approximately 80 patients presenting with native aortic valve stenosis necessitating valve replacement which are considered unsuitable for Surgical Valve Replacement, with a high surgical risk, as attested to by both the surgeon and the cardiologist are recruited in the study.

3. Safety and performance will be evaluated at discharge and at 30 days post procedure. Valve safety, performance and placement will be followed up at 6 and 12 months post-procedure.

Description:

A prospective OPC study to evaluate its performance and long-term safety and effectiveness of Venus-A aortic valve.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: April 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Senile degenerative aortic valve stenosis with echocardiography derived criteria:

mean gradient = 40 mm Hg, or jet velocity = 4.0 m/s, or an aortic valve area (AVA) of < 0.8 cm2 (or AVA index < 0.5 cm2/m2)

• Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class = II

• The subject or the subject's legal representative was informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board of the respective clinical site.

• The subject agreed to comply follow-up evaluation

• is evaluated by at least one cardiologist and two cardiovascular surgeon, and they agreed that medical factors precluding operation suitable for surgery (the probability of death or serious, irreversible morbidity exceeded 50%)

• STS score = 10%

Exclusion Criteria:

• Patient refuses aortic valve replacement surgery.

• Evidence of an acute myocardial infarction = 1 month before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB = twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].

• Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.

• Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).

• Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days (6 month if DES implant)

• Implanted any heart valve prosthesis, prosthetic valve ring, severe mitral valve ring calcification (MAC), severe(>3+)mitral valve insufficiency, or Gorelin symptom

• Blood dyscrasia such as leukopenia (WBC < 3×109/L), acute anemia (Hgb < 90 g/L), thrombocytopenia (PLT < 50×109/L), bleeding diathesis, or history of coagulopathy.

• Untreated clinically significant coronary artery disease requiring revascularization

• Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices

• Need for emergency surgery for any reason

• Hypertrophic cardiomyopathy with or without obstruction (HOCM)

• Severe ventricular dysfunction with LVEF < 20%

• Echocardiographic evidence of intracardiac mass, thrombus or vegetation

• Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months

• A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.

• Native aortic annulus size < 20 mm or> 29 mm as measured by echocardiogram.

• Cerebrovascular Accident (CVA) within 6 months, including TIA.

• Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis.

• Life expectancy < 12 months

• Significant abdominal or thoracic aorta disease, including aneurysm (defined as maximal luminal diameter 5cm or greater), marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding or ulcerated), narrowing of the abdominal aorta (especially with calcification and surface irregularities), or severe "unfolding" and tortuosity of the thoracic aorta

• Iliofemoral vessel characteristics that would preclude safe placement of 16F or 18F introducer sheath such as severe obstructive calcification, severe tortuosity or vessel size diameter < 7 mm.

• Currently participating in an investigational drug or another device study.

• Active bacterial endocarditis or other active infections.

• Bulky calcified aortic valve leaflets in close proximity to coronary ostia

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aortic Valve Calcification
• Aortic Valve Stenosis
• Calcinosis

Intervention

Device:
• Venus MedTech Aortic Valve Prosthesis
Percutaneous implantation of aortic valve of Venus-A

Locations

Country	Name	City	State
China	Fu Wai Hospital, CAMS & PUMA	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Venus MedTech (HangZhou) Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All cause mortality and major stroke at 12 months post-procedure.		12 months post-procedure	Yes
Secondary	Valve performance and placement at 6 and 12 months post-procedure		6 and 12 months post-procedure	No